Related by context. All words. (Click for frequent words.) 72 postoperative mortality 68 perioperative mortality 67 inhospital 67 Operative mortality 65 Stent thrombosis 65 Kaplan Meier estimates 65 noncardiovascular mortality 65 HbA 1c levels 65 postintervention 65 arterial thromboembolic events 64 PASI scores 64 angiographic outcomes 64 angiographic restenosis 64 postoperative infection 64 postoperative complication 63 confidence intervals CIs 63 periprocedural 63 postoperative morbidity 63 CVD mortality 63 multivariable adjustment 63 postprocedure 63 HbA1C levels 63 QALE 62 postdischarge 62 definite stent thrombosis 62 neurodevelopmental impairment 62 % CI #.#-#.# [007] 62 postoperative pulmonary 62 baseline HbA1c 62 % CI #.#-#.# [008] 62 conditional logistic regression 62 p = #.# [003] 62 ratio ICER 61 multivariable adjusted 61 pretest probability 61 pulmonary dysfunction 61 preintervention 61 EDSS scores 61 oxycodone CR 61 oncologic outcomes 61 unplanned readmissions 61 venous thromboembolic disease 61 binary restenosis 61 odds ratios ORs 61 SLNB 61 reinfarction 61 comorbid illnesses 61 ICD implantation 61 sociodemographic factors 61 PDP MLR 61 C diff infections 61 NNT = 61 dose Iluvien 61 CHD mortality 61 MMSE score 60 CI #.#-#.# [001] 60 CPAP adherence 60 NAMCS 60 TAVR 60 FDA defined valvulopathy 60 NIHSS score 60 psychiatric comorbidity 60 PSADT 60 pulmonary capillary wedge 60 plus aztreonam 60 revascularizations 60 prospectively stratified 60 TMP SMX 60 R0 resection 60 IOP lowering 60 postoperative infections 60 ICD therapy 60 PSA nadir 60 ALT elevation 60 psychiatric comorbidities 60 TURBT 60 Hb A1C 60 LV dysfunction 60 candidemia 60 biochemical recurrence 60 SUVmax 59 acute cholecystitis 59 Postoperative complications 59 persistency mortality 59 serum urate 59 ICD implants 59 p = NS 59 perioperative morbidity 59 HBeAg seroconversion 59 neurologic complications 59 hemorrhagic complications 59 pancreatic resection 59 morphometric vertebral fractures 59 mean baseline A1C 59 pCR 59 Complication rates 59 recurrent venous thromboembolism 59 MRSA bloodstream infection 59 Cypher Stent 59 inpatient discharges 59 ARB telmisartan 59 CI #.#-#.# [002] 59 VTE prophylaxis 59 multivariate analyzes 59 severe exacerbations 59 echocardiographic parameters 59 Preterm births 59 postoperative sepsis 59 suboptimal adherence 59 Charlson comorbidity index 59 VAD implantation 59 coronary revascularization procedures 59 rehospitalization 59 IPAH 59 atheroma volume 59 elevated LDH 59 Apgar scores 59 symptomatic VTE 59 symptomatic intracranial 58 Drug eluting stent 58 thromboprophylaxis 58 multivariate adjustment 58 nondiabetic patients 58 confidence interval #.#-#.# 58 rebleeding 58 cecal intubation 58 perinatal outcomes 58 polyp recurrence 58 polyp detection 58 CYPHER ® 58 serum aminotransferase levels 58 multivariable analysis 58 postoperative chemotherapy 58 PSA kinetics 58 perinatal mortality 58 treat NNT 58 CLABSIs 58 aldosterone antagonist 58 nonfatal MI 58 postoperative AF 58 foveal thickness 58 hepatorenal syndrome 58 ICD shocks 58 nonvertebral fracture 58 symptom exacerbation 58 depressive symptom 58 preterm deliveries 58 symptomatic intracranial hemorrhage 58 colorectal cancer incidence 58 vaginal hysterectomy 58 intraoperative complications 58 QTcF 58 androgen suppression 58 % CI #.#-#.# [003] 58 mortality morbidity 58 malignant neoplasm 58 femoral neck fracture 58 microbiological eradication 58 affective psychosis 58 LNG IUS 58 CABG surgeries 58 unstable angina pectoris 58 locoregional recurrence 58 haematologic 58 recurrent ischemia 58 stepwise logistic regression 58 Aloxi injection 58 multivariable analyzes 58 MELD scores 58 everolimus eluting stents 58 recurrent VTE 58 HF hospitalization 58 corticosteroid dose 58 TEAEs 58 posttreatment 58 Logistic regression 58 placebo dexamethasone 58 Readmissions 58 adenoma recurrence 58 postoperative bleeding 58 Renal Cell Carcinoma RCC 58 empyema 58 relapsed MM 58 BRCA2 mutation carriers 58 serum estradiol 58 neutrophil counts 58 patients undergoing CABG 58 Index CDAI 58 MitraClip device 57 estimated GFR 57 virologic failure 57 antipsychotic prescribing 57 ARCALYST ® 57 Thalomid ® 57 de ath 57 deep venous thromboses 57 Kaplan Meier survival 57 hemoglobin A1c levels 57 obstructive CAD 57 adverse perinatal 57 postop 57 comorbid conditions 57 unicompartmental knee arthroplasty 57 identifying beta coefficient 57 revascularization procedure 57 elevated IOP 57 symptomatic intracerebral hemorrhage 57 β blocker 57 postoperative complications 57 experienced virologic failure 57 EuroSCORE 57 nonadherence 57 pooled comparator 57 % CI #.#-#.# [004] 57 extracolonic findings 57 low dose Iluvien 57 univariate analyzes 57 plasma cortisol 57 DAS# remission 57 catheter colonization 57 receiving VICTRELIS 57 imipenem 57 platelet reactivity 57 CR nPR 57 nosocomial infection 57 mediastinitis 57 Skin sterol 57 antibiotic prophylaxis 57 methotrexate monotherapy 57 Viral load 57 analgesic medications 57 NYHA functional class 57 attain statistical significance 57 underwent CABG 57 coronary revascularization 57 decompensated heart failure 57 MACCE 57 postoperative atrial fibrillation 57 YMRS 57 myocardial viability 57 serum sodium levels 57 MMSE scores 57 C. diff infections 57 HSMR 57 preoperative PSA 57 neonatal morbidity 57 EXJADE 57 MADRS score 57 serum creatinine levels 57 ipsilateral stroke 57 perioperative complications 57 glycated hemoglobin levels 57 EDSS score 57 acute myocardial infarctions 57 medication nonadherence 57 lumbar spine BMD 57 sleeve lobectomy 57 Crohn Disease Activity 57 perinatal complications 57 LAGB 57 intima media thickness 57 Febrile neutropenia 57 ELBW infants 57 Preoperatively 57 allogeneic HSCT 57 noncancer 57 acid suppressive medication 57 advanced adenoma 57 oral anticoagulation 57 solifenacin 56 beta blocker therapy 56 CIMZIA ™ 56 nocturnal hypoglycaemia 56 A1c levels 56 Kaplan Meier analysis 56 concomitant AEDs 56 colorectal adenoma 56 perioperatively 56 PMPM basis 56 hepatic resection 56 atrioventricular block 56 mg BID dose 56 posttransplant 56 ADCS CGIC 56 % CI #.#-#.# [006] 56 Coronary artery bypass 56 severe hypoglycaemia 56 glycated hemoglobin HbA1c 56 mechanically ventilated patients 56 DES implantation 56 inhospital complications 56 postoperative delirium 56 SpHb monitoring 56 HealthGrades analyzed 56 MS DRG 56 noncardiac 56 repeat revascularization 56 events MACE 56 DAS# CRP 56 sociodemographic characteristics 56 intrapartum 56 serum clusterin levels 56 Munghana Lonene Listenership 56 lung resections 56 UPPP 56 ARCOXIA 56 HOMA IR 56 univariate 56 symptomatic carotid stenosis 56 XIENCE V PROMUS Stent 56 death reinfarction 56 generalized edema 56 VLBW infants 56 urolithiasis 56 OPCAB 56 Pharmacokinetic parameters 56 fosamprenavir 56 virological response 56 interobserver reliability 56 Hazard Ratio 56 symptomatic hyponatremia 56 logistic regression analysis 56 hepatectomy 56 Hip fracture 56 revascularization procedures 56 BSIs 56 inpatient hospitalizations 56 median survivals 56 morbidity mortality 56 recurrent tonsillitis 56 colon resection 56 Logistic regression analysis 56 transaminase levels 56 preoperative intraoperative 56 ALT flares 56 UPDRS scores 56 prevalences 56 logistic regression models 56 sternal wound infections 56 hypoglycemic events 56 pT3 56 annualized relapse 56 lipid lowering agents 56 DLQI 56 thromboembolic 56 concomitant antibiotics 56 DVT PE 56 segment binary restenosis 56 multivariate logistic regression 56 Ishak fibrosis score 56 MS DRGs 56 carotid artery blockage 56 orofacial clefts 56 atherothrombotic disease 56 Coronary artery bypass grafting 56 TWYNSTA 56 radical nephrectomy 56 reoperations 56 carotid artery stenting CAS 56 confidence interval CI 56 thromboembolism 56 #q# deletion syndrome 56 oral Hycamtin 56 hip BMD 56 anagrelide 56 advanced adenomas 56 secondary efficacy endpoint 56 % Confidence Interval 56 myocardial infarctions MIs 56 SGRQ 56 CHD CVD 56 confirmed thrombotic cardiovascular 56 Caesarean deliveries 56 autonomic dysfunction 56 Coronary artery bypass graft 56 tipranavir r 56 coronary stenosis 56 Thal Dex 56 prolonged QT interval 56 tirofiban 56 dexmedetomidine 56 CHADS2 56 HBV infections 56 nocturnal hypoglycemia 56 invasive aspergillosis 56 diastolic pressures 56 perinatal asphyxia 56 postoperative hemorrhage 56 moderately emetogenic 56 VcMP 56 low birthweights 56 QALYs 56 serologically active patients 55 mRS 55 thromboembolic complications 55 extrapyramidal side 55 APACHE II 55 Carotid endarterectomy 55 univariate analysis 55 logistic regression model 55 cerebrovascular events 55 nadroparin 55 untreated OSA 55 recurrent DVT 55 maternal morbidity 55 nonselective NSAIDs 55 HAM D# scores 55 Zometa hazard 55 VTEs 55 oral olanzapine 55 carotid stenosis 55 SVR# 55 statistically significant predictor 55 Radical prostatectomy 55 timepoints 55 myocardial reperfusion 55 XIENCE V demonstrated 55 nonsignificant 55 NATRECOR R 55 mL/min/#.# m 2 55 pulmonary exacerbations 55 atherosclerotic renal artery stenosis 55 Medicare Advantage MLR 55 epidural analgesia 55 NIHSS 55 divalproex sodium 55 antenatal corticosteroids 55 interferon ribavirin 55 LDB CPR 55 histologic subtype 55 hypofractionated radiation 55 mmHg diastolic 55 Poisson regression 55 COPD exacerbations 55 carotid endarterectomy 55 Infusion Reactions Severe 55 P = .# 55 complete cytogenetic response 55 hip resurfacing arthroplasty 55 subtrochanteric 55 clinically evaluable patients 55 oral hypoglycemic agent 55 CIN3 55 NSTEMI 55 albumin excretion rate 55 fluid overload 55 Preterm infants 55 familial AF 55 intraobserver 55 β blockers 55 glomerular filtration 55 anastomotic leak 55 antidepressant prescribing 55 hematopoietic cancers 55 readmission rates 55 MRSA colonization 55 carotid endarterectomy CEA 55 stent thromboses 55 low birthweight infants 55 intracranial stenosis 55 preterm newborns 55 macrovascular events 55 Coronary Artery Bypass Graft 55 sotalol 55 postoperative radiotherapy 55 Subgroup analyzes 55 neurologic outcomes 55 Hazard Ratio = 55 chorioamnionitis 55 fetal malformations 55 receiving XGEVA 55 MRSA bacteraemia 55 endoscopic remission 55 multivessel disease 55 hemoglobin concentrations 55 FluCAM arm 55 salmeterol fluticasone 55 prespecified secondary 55 prioryear 55 pancreatic fistula 55 oral anticoagulant therapy 55 Secondary efficacy endpoints 55 ACUITY trial 55 RVUs 55 QALY gained 55 C difficile infection 55 MS relapses 55 VT VF 55 sensitivity specificity 55 Kaplan Meier 55 Tumors shrank 55 nonobstructive CAD 55 corneal infection 55 Baseline characteristics 55 doxorubicin docetaxel 55 malabsorptive 55 COPD exacerbation 55 HAQ DI 55 museum Julie Setlock 55 hyperbilirubinemia 55 intravenous diuretics 55 HIV seroconversion 55 tele ICU 55 certolizumab 55 ACR# response 55 Kaplan Meier curves 55 dollar denominated Libor 55 percutaneous vertebroplasty 55 response pCR 55 primary patency 55 adenoma detection 55 C. difficile colitis 55 intraventricular hemorrhage 55 C. diff infection 55 NMIBC 55 debulking surgery 55 nonsevere 55 rho = 55 coronary revascularizations 55 drug eluting stent implantation 55 endarterectomy 55 nonvertebral fractures 55 vessel renarrowing 55 anemia neutropenia 55 acid suppressive medications 55 Readmission 55 estimated glomerular filtration 55 coronary artery bypass grafts 55 recurrent myocardial infarction 55 NSTE ACS 55 neutropaenia 55 achieving PASI 55 extubation 55 LVSD 55 polytherapy 55 salmeterol HFA MDI 55 nonfasting triglycerides 55 warfarin therapy 55 comorbidities 55 recurrent UTI 54 dalteparin 54 asthma exacerbation 54 dose atorvastatin 54 warfarin dosage 54 hemoglobin A1c HbA1c 54 ximelagatran 54 BMI z 54 HORIZONS AMI trial 54 dose dabigatran 54 ETDRS 54 HER2 expression 54 upper gastrointestinal bleeding 54 nausea dizziness vomiting 54 spirometric 54 oligohydramnios 54 Serum creatinine 54 urine albumin 54 IV bisphosphonates 54 logistic regression analyzes 54 Breslow thickness 54 MCyR 54 Mantel Haenszel 54 ziprasidone 54 sustained virological response 54 multivariate regression analysis 54 QTc prolongation 54 adenoidectomy 54 cardiovascular hospitalizations 54 serum phosphorous 54 adnexal mass 54 serum calcium levels 54 plain radiographs 54 microbiologically evaluable 54 FOLFIRI alone 54 linaclotide treated 54 SRBD 54 adjunctive placebo 54 PREZISTA r arm 54 invasive fungal infection 54 Nonresidential structures 54 intensive statin therapy 54 troponin T 54 asymptomatic PAD 54 NSQIP 54 epoetin therapy 54 comorbid diagnoses 54 affective psychoses 54 acute respiratory tract infections 54 noncardiovascular 54 Homocysteine levels 54 uninfected chimps 54 serum lipid levels 54 AST ALT 54 hematologic parameters 54 GIK infusion 54 HAART initiation 54 LTCHs 54 acute decompensation 54 ATACAND 54 antiplatelet medication 54 lymphocyte count 54 virologic response 54 seropositivity 54 serum urate levels 54 Clostridium difficile infections 54 salpingo oophorectomy 54 thyrotropin levels 54 laparoscopic appendectomy 54 achieved CCyR 54 carotid revascularization 54 coinfected patients 54 noncardiac surgery 54 Colorectal cancer screening 54 APTIVUS r 54 gastrointestinal bleeds 54 elevated bilirubin 54 interquartile range 54 Demographers attribute 54 invasive prenatal 54 caesarean deliveries 54 Soliris therapy 54 moderate renal impairment 54 eculizumab therapy 54 wound dehiscence 54 neurodevelopmental outcome 54 Colorectal cancer incidence 54 related bloodstream infections 54 preoperative chemotherapy 54 liver transplant recipients 54 CI -#.# 54 retransplantation 54 INRs 54 IFN alfa 54 adefovir treated 54 underwent coronary angiography 54 parous women 54 unresectable HCC 54 CDI recurrence 54 cardiopulmonary diseases 54 ECD kidneys 54 thrombotic events 54 -#.# log# 54 hematologic toxicity 54 undetectable PSA 54 severe asthma exacerbations 54 6MWD 54 nulliparous women 54 LTCH 54 antiretroviral naïve 54 multiple gestations 54 CP CPPS 54 Postoperative 54 cerebral oxygen saturation 54 paliperidone ER 54 Erythropoietic therapies may 54 HAM D# 54 recurrent ischemic stroke 54 Non inferiority 54 invasive candidiasis 54 Heavy menstrual bleeding 54 nonfatal myocardial infarction MI 54 ALND 54 RUGs IV 54 subthreshold depression 54 lung resection 54 tapentadol ER 54 bariatric surgical 54 sustained ventricular tachycardia 54 % CI #.#-#.# [001] 54 KRAS status 54 nighttime awakenings 54 biopsy Gleason 54 LTCH PPS 54 ASCUS 54 Hospitalisation 54 FOLFOX4 54 postvaccination 54 NATRECOR ® 54 MoxDuo TM IR 54 albumin excretion 54 PLX STROKE targeting 54 esophagectomy 54 acute myocardial infarction MI 54 biochemical relapse 54 IVF pregnancies 54 postsurgical 54 assets RoA 54 placenta accreta 54 clinicopathological features 54 spontaneous vaginal 54 valvulopathy 54 leukocyte count 54 hsCRP levels 54 Aortic stenosis 54 calculated creatinine clearance 54 inhaled budesonide 54 graft occlusion 54 Adjuvant chemotherapy 54 TAXUS p value 54 extrapyramidal symptoms 54 INVEGA ® 54 comorbidity 54 nonfatal myocardial infarction 54 5-fluorouracil/leucovorin 54 knee arthroplasty 54 gauge vitrectomy 54 antibiotic prescribing 54 unfractionated heparin UFH 54 ROC curve 53 triglyceride concentration 53 SCr 53 axillary node dissection 53 hematological parameters 53 cerebral oxygenation 53 chemoradiation therapy 53 asymptomatic carotid stenosis 53 procalcitonin 53 endometrial carcinoma 53 1mg dose 53 PCIs 53 nonteaching hospitals 53 mammographic density 53 Visual acuity 53 Events MACE 53 bivalirudin monotherapy 53 dyspnoea 53 Prepaid churn 53 cranial irradiation 53 lopinavir r arm 53 bronchopulmonary dysplasia BPD 53 abnormal mammograms 53 cytologic 53 nonoperative treatment 53 Angioplasties 53 statistical significance p 53 Cesarean deliveries 53 Celsentri Selzentry 53 intracerebral haemorrhage 53 prospectively defined 53 multivariable logistic regression 53 intravascular hemolysis 53 adjuvant radiotherapy 53 atorvastatin #mg 53 mcg QD 53 sustained virologic response 53 placebo fluoxetine 53 Platelet counts 53 dysmenorrhoea 53 RYGB 53 undetectable HBV DNA 53 antithrombotic therapy 53 seroprotection 53 cesarean births 53 Multivariate analysis revealed 53 CMV infection 53 incidence ≥ 53 nonobese patients 53 venlafaxine XR 53 NIH CPSI 53 transaminase elevations 53 Flu Cy 53 radical prostatectomy RP 53 arterial oxygen saturation 53 NYHA classification 53 peri procedural 53 TPV r 53 ADHF 53 familial aggregation 53 nonsignificant difference 53 malfunctioning pacemakers 53 nonfasting triglyceride levels 53 haemorrhagic stroke 53 Kaplan Meier method 53 potent antiretroviral therapy 53 neurodevelopmental outcomes 53 glomerular filtration rate 53 syncopal 53 elevated ALT 53 glycosylated hemoglobin levels 53 contrast induced nephropathy 53 covariate 53 Ejection Fraction 53 IBDQ 53 malignant neoplasms 53 prolactin elevation 53 CsA 53 amenorrhoea 53 nonmelanoma skin cancers 53 cystoscopic 53 thrombocytopenic 53 mg Proellex 53 DRGs 53 tamoxifen Nolvadex ® 53 adenotonsillectomy 53 Neonatal mortality 53 pneumococcal vaccination 53 RSV hospitalizations 53 Doxil ® 53 acromegalic patients 53 Secondary endpoints included 53 coronary interventions 53 Taxus Stent 53 spontaneous circulation ROSC 53 salivary flow 53 Partial Response 53 incomplete revascularization 53 GI bleeds 53 exhaled NO 53 mcg albinterferon alfa 2b 53 hypokalemia 53 refractory ischemia 53 MDRD 53 % CI #.#-#.# [005] 53 non valvular atrial 53 invasive MRSA infections 53 guideline concordant 53 SYNERGY Stent 53 P ≤ 53 suicide ideation 53 pulmonary artery catheterization 53 baseline FEV 53 SHKPI 53 Rectal cancer 53 FTE staffing 53 adverse cytogenetics 53 Hazard Ratio HR 53 ejection fractions 53 dacarbazine chemotherapy 53 CCyR 53 endometrial thickness 53 hypoglycemic episodes 53 enhanced sonography 53 cilostazol 53 mcg Albuferon 53 Secondary endpoints include 53 Summarized consolidated 53 gestational diabetes mellitus GDM 53 lymphocytosis 53 Severity MSCS score 53 elevated fasting glucose 53 peak VO2 53 coronary CTA 53 oral diclofenac 53 desvenlafaxine succinate 53 Preterm babies 53 arterial stenosis 53 antimicrobial prophylaxis 53 tertiles 53 nephron sparing surgery 53 IRLS score 53 alteplase 53 meta regression 53 locoregional 53 steroid dexamethasone 53 triplet births 53 ejaculatory function 53 XEPLION R 53 POAG 53 renal transplants 53 pyrexia mucositis sepsis febrile 53 lobular cancer 53 antenatal depression 53 fragility fracture 53 reintubation 53 cTnT levels 53 F FDG PET 53 clodronate 53 Mortality 53 Bloodstream infections 53 labetalol 53 systemic embolism 53 indicates cardio circulatory 53 psychiatric morbidity 53 reserve reestimates 53 ACR Pedi 53 chronic LBP 53 QIDS SR 53 Scheuermann kyphosis 53 activated partial thromboplastin 53 serum cortisol 53 baseline A1C 53 HSCT 53 baseline LDH 53 achieving hemostasis 53 progression TTP 53 Oxy ER 53 Score DAS# 53 undergoing radical prostatectomy 53 statistically significant p = 53 liver metastasis 53 nonhospital providers 53 REMINYL ® 53 metabolic dysregulation 53 percutaneous drainage 53 clinically evaluable population 53 symptomatic aortic stenosis 53 nausea emesis 53 glutamate glutamine 53 severe hypoglycemic 53 HBeAg negative patients 53 neurologic dysfunction 53 confirmed CCyR 53 STN stimulation 53 Univariate 53 hyperkinetic disorder 53 pamidronate 53 interobserver 53 elective PCI 53 xi fluctuating currency 53 paroxysmal AF 53 R# #mg BID 53 prednisone prednisolone 53 bivariate 53 directed thrombolysis 53 HbA1C 53 estrogen progestin therapy 53 diameter stenosis 53 intra abdominal abscess 53 radioiodine therapy 53 carotid IMT 53 hyperprolactinemia 53 prognostic variables 53 ADEs 53 elevated LDL cholesterol 53 acute STEMI 53 ofpatients 53 intravesical therapy 53 Billable headcount 53 restenosis reblockage 53 endophthalmitis 53 ischemic lesions 53 Fasting blood glucose 53 cardiac revascularization 53 percutaneous intervention 53 IM progesterone 53 abdominal adiposity 53 acute myocardial infarction AMI 53 CR CRu 53 Triglyceride levels 53 arterial thickening 53 mortality 53 Fasting plasma glucose 53 perinatal morbidity 53 TMC# r 53 mg XP# 53 serum BDNF 53 p = .# [002] 53 HACs 53 SYKES Enterprises NASDAQ SYKE 53 atypical ductal hyperplasia 53 potential confounding variables 53 Diastolic pressure 53 vaginal hysterectomies 53 drotrecogin alfa activated 53 serum sodium 53 STELARA ® 53 urinary albumin excretion 53 antiarrhythmic drug 53 Natalizumab 52 CTEPH 52 ruptured aneurysms 52 coronary angiograms 52 nonobese 52 multivariate Cox 52 covariates 52 Depressive symptoms 52 nonsurgical cosmetic procedures 52 peripartum 52 eosinophilic pneumonia 52 dose statin therapy 52 creatinine clearance CrCl 52 HIV coinfected 52 syncopal episodes 52 alanine aminotransferase 52 NHAMCS 52 fibrinolytic therapy 52 comorbid disorders 52 mineral density BMD 52 HBeAg 52 Preterm delivery 52 TroVax ® 52 SYNTAX trial 52 Interrater reliability 52 nodal metastases 52 FROVA 52 residual confounding 52 OAB symptoms 52 amoxicillin clavulanate 52 dysrhythmias 52 symptom flare ups 52 reinterventions 52 tumor histology 52 CFQ R 52 somatoform disorders 52 acute rheumatic fever 52 Pneumococcal vaccination 52 Uncontrolled hypertension 52 pulmonary resection 52 homocysteine concentrations